Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia | Zendy

Daoud AlBadriyeh | Zendy; Danny Liew | Zendy; K. Stewart | Zendy; David C. M. Kong | Zendy

Open Access

Economic impact of caspofungin as compared with liposomal amphotericin B for empirical therapy in febrile neutropenia in Australia

Author(s) -

Daoud AlBadriyeh,

Danny Liew,

K. Stewart,

David C. M. Kong

Publication year - 2009

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkp119

Subject(s) - caspofungin , neutropenia , medicine , febrile neutropenia , empirical treatment , intensive care medicine , amphotericin b , antibiotics , chemotherapy , microbiology and biotechnology , antifungal , biology , dermatology

In a major clinical trial, caspofungin was as efficacious as liposomal amphotericin B (LAmB) for empirical therapy in febrile neutropenia. The current study sought to evaluate the economic impact of caspofungin as compared with LAmB for febrile neutropenia in Australia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research